Jeff Yass’s AtriCure ATRC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $341K | Buy |
12,200
+2,400
| +24% | +$67.5K | ﹤0.01% | 10763 |
|
|
2026
Q1 | $280K | Sell |
9,800
-22,700
| -70% | -$775K | ﹤0.01% | 11032 |
|
|
2025
Q4 | $1.29M | Buy |
32,500
+12,800
| +65% | +$469K | ﹤0.01% | 6603 |
|
|
2025
Q3 | $694K | Sell |
19,700
-3,500
| -15% | -$121K | ﹤0.01% | 8213 |
|
|
2025
Q2 | $760K | Sell |
23,200
-2,500
| -10% | -$81.2K | ﹤0.01% | 8148 |
|
|
2025
Q1 | $829K | Buy |
25,700
+12,200
| +90% | +$453K | ﹤0.01% | 7726 |
|
|
2024
Q4 | $413K | Buy |
+13,500
| New | +$434K | ﹤0.01% | 9137 |
|
|
2024
Q3 | – | Sell |
-88,200
| Closed | -$2.01M | – | 11927 |
|
|
2024
Q2 | $2.01M | Buy |
88,200
+62,300
| +241% | +$1.44M | ﹤0.01% | 5097 |
|
|
2024
Q1 | $788K | Buy |
25,900
+20,000
| +339% | +$670K | ﹤0.01% | 7444 |
|
|
2023
Q4 | $211K | Buy |
+5,900
| New | +$219K | ﹤0.01% | 10576 |
|
|
2023
Q3 | – | Sell |
-6,900
| Closed | -$341K | – | 11982 |
|
|
2023
Q2 | $341K | Buy |
6,900
+1,600
| +30% | +$73.7K | ﹤0.01% | 9181 |
|
|
2023
Q1 | $220K | Sell |
5,300
-900
| -15% | -$37.3K | ﹤0.01% | 10395 |
|
|
2022
Q4 | $275K | Buy |
+6,200
| New | +$259K | ﹤0.01% | 9298 |
|
|
2022
Q1 | – | Sell |
-4,200
| Closed | -$292K | – | 12941 |
|
|
2021
Q4 | $292K | Sell |
4,200
-1,000
| -19% | -$72.7K | ﹤0.01% | 10558 |
|
|
2021
Q3 | $362K | Sell |
5,200
-2,100
| -29% | -$162K | ﹤0.01% | 10156 |
|
|
2021
Q2 | $579K | Buy |
7,300
+3,300
| +83% | +$240K | ﹤0.01% | 9243 |
|
|
2021
Q1 | $262K | Buy |
4,000
+200
| +5% | +$12.3K | ﹤0.01% | 10886 |
|
|
2020
Q4 | $212K | Sell |
3,800
-4,700
| -55% | -$203K | ﹤0.01% | 9940 |
|
|
2020
Q3 | $339K | Sell |
8,500
-7,800
| -48% | -$331K | ﹤0.01% | 8461 |
|
|
2020
Q2 | $733K | Buy |
16,300
+1,300
| +9% | +$56.6K | ﹤0.01% | 6570 |
|
|
2020
Q1 | $504K | Buy |
15,000
+5,300
| +55% | +$191K | ﹤0.01% | 6918 |
|
|
2019
Q4 | $315K | Sell |
9,700
-19,700
| -67% | -$561K | ﹤0.01% | 7916 |
|
|
2019
Q3 | $733K | Buy |
29,400
+18,000
| +158% | +$514K | ﹤0.01% | 6400 |
|
|
2019
Q2 | $340K | Buy |
+11,400
| New | +$333K | ﹤0.01% | 8074 |
|
|
2019
Q1 | – | Sell |
-9,800
| Closed | -$300K | – | 8787 |
|
|
2018
Q4 | $300K | Buy |
9,800
+800
| +9% | +$24.9K | ﹤0.01% | 6996 |
|
|
2018
Q3 | $315K | Buy |
+9,000
| New | +$285K | ﹤0.01% | 7394 |
|
|
2017
Q3 | – | Sell |
-12,700
| Closed | -$308K | – | 8780 |
|
|
2017
Q2 | $308K | Buy |
+12,700
| New | +$270K | ﹤0.01% | 7545 |
|
|
2016
Q4 | – | Sell |
-15,300
| Closed | -$242K | – | 9543 |
|
|
2016
Q3 | $242K | Sell |
15,300
-700
| -4% | -$10.8K | ﹤0.01% | 7276 |
|
|
2016
Q2 | $226K | Buy |
+16,000
| New | +$244K | ﹤0.01% | 7401 |
|
Other funds holding ATRC
HRCM
NAMI
Jeff Yass's ATRC Position: Q2 2026 in Review
Jeff Yass reduced its AtriCure (ATRC) stake by 63% in Q2 2026, selling an estimated $685K and leaving 14,450 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #10384.
Jeff Yass first reported a position in ATRC in Q4 2016 and has held it in 23 quarters since. The position peaked at $2.51M in Q1 2020. 250 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.
- Jeff Yass held 14,450 shares of AtriCure worth $404K as of Q2 2026.
- Jeff Yass sold 24,327 AtriCure shares in Q2 2026, an estimated $685K.
- AtriCure made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10384 holding.
- Jeff Yass first reported a position in AtriCure in Q4 2016 and has held it in 23 quarters since.
- Jeff Yass's AtriCure position peaked at $2.51M in Q1 2020.
- 250 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.